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Abstract TNF-K converting enzyme (TACE; ADAM-17) is a
membrane-bound disintegrin metalloproteinase that processes
the membrane-associated cytokine proTNF-K to a soluble form.
Because of its putative involvement in inflammatory diseases,
TACE represents a significant target for the design of specific
synthetic inhibitors as therapeutic agents. In order to study its
inhibition by tissue inhibitors of metalloproteinases (TIMPs) and
synthetic inhibitors of metalloproteinases, the catalytic domain
of mouse TACE (rTACE) was overexpressed as a soluble Ig
fusion protein from NS0 cells. rTACE was found to be well
inhibited by peptide hydroxamate inhibitors as well as by TIMP-
3 but not by TIMP-1, -2 and -4. These results suggest that
TIMP-3, unlike the other TIMPs, may be important in the
modulation of pathological events in which TNF-K secretion is
involved.
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1. Introduction
Tumour necrosis factor-K (TNF-K) is a cytokine produced
in response to infection or injury and identi¢ed as a major
mediator of chronic autoimmune diseases such as rheumatoid
arthritis and in£ammatory pathologies such as sepsis [1].
ProTNF-K is initially produced as a membrane-bound form
that is processed by TNF-K converting enzyme (TACE), a
recently identi¢ed type I membrane-bound metalloproteinase
[2,3]. TACE represents a potential target for the development
of therapeutic agents for in£ammation and related diseases
[4]. TACE is a member of the ADAM (A disintegrin and
metalloprotease) family of proteins which have been impli-
cated in cell interaction events including cell fusion [5,6] and
has been designated ADAM-17. TACE has a higher sequence
identity with MADM (ADAM-10) than any other mammali-
an ADAMs [2]. MADM was originally implicated in myelin
degradation [7], but was recently shown to be potentially ca-
pable of processing proTNF-K to its soluble form [8,9]. The
Drosophila ADAM-10 orthologue, KUZ, can cleave the ex-
tracellular portion of the transmembrane receptor protein
Notch which has been implicated in cell fate determination.
Notch processing is probably a required step in the synthesis
of a functional receptor [10].
The X-ray crystal structure of the catalytic domain of hu-
man TACE shows similarities with that of the snake venom
metalloproteinase adamalysin II [11]. Snake venom metallo-
proteinases and ADAMs are included in the wider family of
metalloproteinases, the metzincins [12], which also contains
the matrix metalloproteinases (MMPs), involved in the degra-
dation of extracellular matrix. MMP activities are regulated
by a group of physiological inhibitors, the tissue inhibitors of
metalloproteinases (TIMPs) [13^15]. The question of the abil-
ity of these inhibitors to act on ADAMs has been raised
[11,16]. However, TIMP-1 or -2 did not inhibit the processing
of proTNF-K [17] or the shedding of the adhesion molecule L-
selectin [18], excluding the participation of any of the MMPs
characterised so far. More recent evidence indicates that shed-
ding of receptors to cytokines such as TNF and IL-6 is in-
hibited by TIMP-3 [19,20].
One important issue is whether TACE is involved in the
shedding of membrane proteins other than proTNF-K [21].
In common with as yet unidenti¢ed enzymes known as ‘sec-
retases’ or ‘sheddases’, TACE is inhibited by broad spectrum
synthetic MMP inhibitors and upregulated by phorbol esters
[22]. In this report, we describe the expression and puri¢cation
of the metalloproteinase domain of mouse TACE and the
comparative study of its inhibition by TIMPs and synthetic
inhibitors designed for MMPs.
2. Materials and methods
2.1. Materials and general procedures
Fmoc amino acids were from Alexis Corporation (Nottingham,
UK). Fmoc-Lys(Dnp)-OH was made as described [23]. HATU,
HOAt and Fmoc-PAL-PEG-PS resin were from PerSeptive Biosys-
tems (Hertford, UK). BB-94 was from British Biotech Pharmaceuti-
cals Ltd (Oxford, UK). Ro-31-9790 was from Roche (Welwyn Garden
City, UK). Protein A-Sepharose, soybean trypsin inhibitor and 7-me-
thoxycoumarin-4-acetic acid were from Sigma (Poole, UK). Recombi-
nant enterokinase (1.7 unit/Wl, where 1 unit is de¢ned as the amount
of enzyme needed to cleave 50 Wg of fusion protein in 16 h) was from
Novagen (Cambridge Bioscience, Cambridge, UK). Recombinant hu-
man TIMP-1, -2 and -3 were expressed in NS0 mouse myeloma cells
and puri¢ed as previously described [13,24]. Full-length mouse TIMP-
4 was expressed from E. coli and refolded (manuscript in preparation).
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Recombinant progelatinase-A (proMMP-2) was puri¢ed from condi-
tioned medium from transfected mammalian cell lines and activated
as described previously [24].
Unless indicated otherwise, all £uorimetric measurements were
made with a LS50B Perkin-Elmer spectro£uorimeter (Vex = 328 nm,
Vem = 393 nm) equipped with thermostable cuvette holders (37‡C) in
2.5 ml of bu¡er A (10 mM HEPES, pH 7.5, 0.02% NaN3, 0.05%
Brij35) with constant amount of DMSO (2% v/v). Kinetic analyses
were achieved with the software package GraFit 3.0 (Erithacus Soft-
ware Ltd, Staines, Middlesex, UK).
HPLC analyses were done on a Perkin-Elmer Integral 4000 instru-
ment equipped with a Vydac 218TP54 column maintained at 40‡C.
Solvents were: A, 0.1% TFA in water; B, 0.08% TFA in acetonitrile.
A linear gradient from 5 to 95% B was run over 20 min at 1.25 ml/min
and the eluate was monitored at 230 and 335 nm.
2.2. cDNA cloning of mouse TACE and expression of the
catalytic domain
Poly A RNA was separated by oligo-dT spin chromatography
(Pharmacia) from total RNA isolated from NS0 cells (ECACC
No. 85110503) by the method of Chomczynski and Sacchi [25]. It
was converted into a cDNA library of approximately 106 individual
clones in lambda ZAPII according to the protocol provided by the
supplier (Stratagene, Amsterdam, Netherlands). The library was
plated out and pooled into 10 aliquots which were each converted
into a population of cDNAs in pBluescript (Stratagene). Murine
TACE cDNA was ampli¢ed from one aliquot by PCR using the




Following TA subcloning in pMOSblue (Amersham) six independ-
ent clones containing the resulting 2.5 kb fragment were sequenced
using an ABI 373A automated sequencer and a consensus sequence
was established (Accession number AJ007365). It was used as a tem-
plate together with the 5P oligonucleotide described above and a sec-
ond oligonucleotide (5P-GAGAGAGTCGACCACCTTGTTGCTGC-
GCTCCTGG-3P) to PCR amplify a DNA fragment encoding the pre
pro catalytic domain. The resulting DNA fragment has a 3P Sal1 site
(underlined) that replaces the sequence in TACE that encodes amino
acids C478 G479 found at the start of the disintegrin domain. It also
has a 5P Xba1 site upstream of the initiating methionine codon, ATG
(also underlined). It was ligated into a version of pEE12 [26] such that
it was joined at the Sal1 site to a sequence encoding the human IgG1
heavy chain constant region, hinge, CH1 and CH2 domains. A DNA
adapter encoding an enterokinase cleavage site ([V]DDDDK) was
then introduced at the Sal1 site. The vector was transfected into
mouse NS0 myeloma cells and the most productive clones were iden-
ti¢ed by two site ELISA for the human IgG Fc domain [27] and then
grown up in serum-free media as described [28]. The vector was also
used to generate serum-free conditioned media following its transient
expression in CHO-L761h cells as previously described [29].
2.3. Puri¢cation of rTACE
Conditioned medium was mixed with an equal volume (25 ml) of
bu¡er A and batch-bound for 16 h at 4‡C to 0.5 ml of Protein A-
Sepharose previously equilibrated with bu¡er A. The resin was
washed with 50 ml of bu¡er A containing 0.5 M NaCl prior to addi-
tion of 2.5 ml of bu¡er A containing 50 mM NaCl, 2 mM CaCl2 and
10 units of recombinant enterokinase. The slurry was agitated for 16 h
at room temperature and then for a further hour in presence of 100
Wg/ml of soybean trypsin inhibitor to inactivate the enterokinase. The
supernatant was removed from the resin and the eluted protein ana-
lysed by SDS-PAGE (10% polyacrylamide) under reducing conditions
and by N-terminal sequencing.
N-terminal sequence analysis was obtained as follows: 5 Wg of
puri¢ed TACE was analysed by SDS-PAGE (4^20% polyacrylamide
gradient gel, NOVEX), and the protein was electrophoretically trans-
ferred to a PVDF membrane (Immobilon P, Millipore). The mem-
brane was stained with Ponceau Red, washed extensively with distilled
water, and the band corresponding to TACE was excised for N-ter-
minal sequencing using an Applied Biosystems 470 microsequencer.
2.4. Synthesis of QF-45 and QF-48
The quenched £uorescent substrates Mca-Ser-Pro-Leu-Ala-Gln-
Ala-Val-Arg-Ser-Ser-Ser-Arg-Lys(Dnp)-NH2 (QF-45) and Mca-Ser-
Ser-Met-Ala-Gln-Thr-Leu-Thr-Leu-Arg-Ser-Ser-Ser-Lys(Dnp)-NH2
(QF-48) are based on the TACE-sensitive sequences in human and
mouse TNF-K, respectively. QF-45 and QF-48 were synthesised as C-
terminal amides on Fmoc-PAL-PEG-PS resin in a PerSeptive Biosys-
tems 9050 Plus PepSynthesiser. Brie£y, Fmoc amino acids (4 eq.) were
activated with HATU (4 eq.) in the presence of diisopropylethylamine
(8 eq.) [30]. HOAt (4 eq.) was added when coupling Gln. Fmoc de-
protection was with a mixture of 2% (v/v) piperidine and 2% (v/v) 1,8-
diazabicyclo[5,4,0]undec-7-ene. For the coupling of 7-methoxycou-
marin-4-acetic acid (4 eq.), the resin was gently shaken with HATU
(4 eq.) in the minimum volume of dimethylformamide. A second
portion of HATU was added after 4 h and the reaction was allowed
to proceed to completion overnight. Peptides were released by treat-
ment with TFA/water/triisopropylsilane (92.5:5:2.5, by vol.) for 2 h at
21‡C, applied to a column of Vydac 218TPB1520 and eluted with a
gradient of 5 to 50% acetonitrile in 0.1% TFA. Fractions containing
homogeneous product were identi¢ed by analytical HPLC, pooled
and freeze-dried. The identity of the puri¢ed peptides was con¢rmed
by matrix-assisted laser desorption-ionisation mass spectrometry.
2.5. Enzyme assays and identi¢cation of cleavage products
Initial velocities (Vi) corresponding to the rTACE-catalysed hydrol-
yses of QF-48 (0.2 to 0.8 WM) and QF-45 (0.2 to 2 WM) were recorded
at concentrations of substrate well below the Michaelis constant
(SIKM). Under these conditions, catalytic e⁄ciencies (kcat/KM)
were derived by linear regression of the simpli¢ed Michaelis equation:
Vi = (kcat/KM)UEoUS. The enzyme concentration Eo was determined
as described below. The e¡ect of pH was observed from pH 6.0 to
11.0 in bu¡er 20 mM MES, 20 mM Tris, 20 mM CAPS. The in£uence
of ionic strength over enzyme activity was examined by adding so-
dium chloride (0 to 0.5 M) to bu¡er A. The requirement for metal
ions was examined after 1 h incubation in presence of 1 mM of EDTA
followed by addition of 2 mM CaCl2, ZnCl2 or MgCl2.
The quenched £uorescent substrates QF-45 (10 WM) and QF-48
(5 WM) were incubated for 16 h at 37‡C with 100 nM rTACE. An
initial HPLC analysis with 10 Wl of each digest showed that the cleav-
age products were well separated. 300 Wl of each digestion sample was
then fractionated by HPLC and the eluate was collected at 0.5 min
intervals. Fractions containing the products were dried in vacuo over
P2O5 and submitted for mass spectrometry by Dr L.C. Packman
(Cambridge Centre for Molecular Recognition). No hydrolysis of
QF-45 and QF-48 was obtained in control assays where rTACE
was excluded.
2.6. Inhibition procedures
Reaction mixtures between rTACE (V1 nM) and inhibitors were
pre-incubated 2 h at 37‡C with TIMP-1 (0 to 152 nM), TIMP-2 (0 to
128 nM), TIMP-4 (0 to 115 nM), CT-2256 (0 to 25 nM), BB-94 (0 to
25 nM), Ro-31-9790 (0 to 250 nM), CT-420 (0 to 1 WM), CT-548 (0 to
24 WM) and CT-1746 (0 to 1 WM). The steady-state velocities Vs were
measured with QF-45 (1 WM). Apparent inhibition constants Ki 0
(equal to Ki(1+S/KM)) and Eo were estimated by least-squares ¢t to
Eq. 1 for competitive tight-binding inhibition [31]:
Vs  Vo=2EoU Eo3Io3Ki 0  Eo3Io3Ki 02  4EoKi 01=2g;
n
1
where Io and Vo are total concentration of inhibitor and velocity in
absence of inhibitor, respectively. The same method was used for the
inhibition of rTACE by TIMP-3 (0 to 0.77 nM) and of MMP-2 (V0.1
nM) by TIMP-1, -3 and -4 (0 to 90 pM), except the pre-incubation
periods were extended to 16 h. MMP-2 activity was followed at 25‡C
with 1 WM of the £uorogenic peptide Mca-Pro-Leu-Gly-Leu-Dpa-Ala-
Arg-NH2 (QF-24) in 100 mM Tris (pH 7.5), 150 mM NaCl, 10 mM
CaCl2, 0.05% Brij35 and 0.02% NaN3.
The association rate constant (kon) of rTACE with TIMP-3
was estimated as previously published [24]. The dissociation rate
constant (koff ) was determined by initially incubating rTACE and
TIMP-3 at an equimolar concentration of 100 nM and diluting 0.5
to 2.5 Wl of the preformed enzyme-inhibitor complex into 2.5 ml of
assay bu¡er containing 1 WM QF-45. Recovery of enzyme activity was
followed for 5 h. Estimates of koff have been calculated as previously
published [24]. The method employed for determining an overall dis-
sociation constant (KD) for MMP-2 and TIMP-2 is described else-
where [32].
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3. Results and discussion
3.1. Amino acid sequence of murine TACE
Comparison of the predicted amino acid sequence of mur-
ine and human TACE reveals a high degree of sequence con-
servation (92.6% identity). When compared with other mam-
malian ADAMs, both versions of TACE are clearly more
closely related to MADM than to other members of this fam-
ily [2]. This is particularly apparent within the catalytic do-
main, where TACE and MADM share a conserved arrange-
ment of six cysteine residues that di¡ers signi¢cantly from the
other family members. This may have relevance to the cata-
lytic properties of the two enzymes, as both are reported to
cleave proTNF-K [8,9]. Currently it is not clear whether one
or both enzymes play this important role in vivo. Similarly it
is not known whether TACE shares the ability of MADM to
cleave Notch.
3.2. Puri¢cation of rTACE
Puri¢ed recombinant TACE catalytic domain was analysed
by SDS-PAGE, and N-terminal sequencing. rTACE was re-
leased from the Fc fusion through cleavage at an engineered
enterokinase site at the C-terminus of the catalytic domain
(Fig. 1A). The resulting protein had an apparent molecular
weight of 43 kDa as analysed by SDS-PAGE and Coomassie
staining (Fig. 1B). N-terminal sequencing of the puri¢ed ma-
terial identi¢ed two species sequences present in equal
amounts, VKRRAEPN and RAEPNPLK, with the N-termi-
nal residues being Val-212 and Arg-215 respectively. N-termi-
nal sequencing of human TACE, expressed in CHO cells [11]
revealed processing at the same two sites, indicating that the
dual cleavage sites may be an authentic part of the activation
pathway, presumably involving a furin-like enzyme [2,3].
In conclusion the recombinant TACE puri¢ed and used in
this study, has an apparent molecular weight (43 kDa) and N-
terminal sequence consistent with it being the bona ¢de cata-
lytic domain of the enzyme (Fig. 1).
3.3. Activity of rTACE
rTACE cleaved peptide substrates covering the cleavage
sites of human and mouse proTNF-K (QF-45 and QF-48).
HPLC analysis showed that both substrates were cleaved at
a single site. The molecular masses of the end products were
consistent with rTACE-catalysed hydrolysis occurring at the
following peptide bonds (-s-) : -Leu-Thr-s-Leu-Arg- (QF-48)
and -Gln-Ala-s-Val-Arg- (QF-45). These results revealed that
rTACE cleaved QF-48 and QF-45 at the processing sites of
mouse and human proTNF-K, respectively. The selective
cleavage of the second Thr-Leu bond in QF-48 emphasised
the importance of the residues surrounding the cleaved bond
in determining substrate speci¢city. The catalytic e⁄ciencies
(kcat/KM) for the rTACE-catalysed hydrolysis of QF-45 and
QF-48 obtained at 37‡C by £uorimetry had values of
1.3( þ 0.1)U105 and 3.5( þ 0.4)U103 M31 s31, respectively.
Thus the human TNF-K based peptide was hydrolysed 37
times more rapidly by the catalytic domain of mouse TACE
than the mouse TNF-K based peptide. TNF-K converting ac-
tivity, partially puri¢ed from a human monocytic cell line
(THP-1), processed human proTNF-K, but did not cleave
mouse proTNF-K [33]. These data suggest that peptides based
on mouse proTNF-K are poor in vitro substrates of both
human and murine TACE. Interestingly, the £uorogenic pep-
tide QF-24, which is cleaved by most MMPs between Gly and
Leu, is also a mediocre rTACE substrate. The calculated cat-
alytic e⁄ciency for rTACE-catalysed hydrolysis of QF-24
(kcat/KM = 1.2( þ 0.1)U103 M31 s31 at 37‡C) is 500-fold lower
than that reported for MMP-2 [34].
rTACE activity was inhibited by EDTA, but inhibition
could be reversed by incubation with Zn2. Other metal
ions tested (Ca2 and Mg2) did not reactivate the enzyme,
providing evidence for the speci¢city of the Zn2 for the cat-
alytic activity of rTACE. Activity of MADM had previously
been reported to be higher at pH values between 9 and 10 [8].
Similarly, rTACE was active within a pH range of 6 to 10.5
(data not shown), with the enzymatic activity increasing 7-fold
from pH 6.5 to 10 (its optimum pH). At pH 10.5, rTACE was
still active, but less stable (t1=2V10 min). The presence of 0.5
M NaCl had no notable e¡ect on rTACE activity.
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Fig. 1. A: Schematic representation of the TACE pre pro catalytic
domain expressed as a Fc fusion. The arrowheads to the left indi-
cate the propeptide processing sites as determined by N-terminal se-
quencing. The arrowhead to the right indicates the anticipated
cleavage that occurs after treatment with enterokinase. B: Coomas-
sie stained SDS-PAGE of puri¢ed rTACE. The fusion protein could
be bound through the Fc portion to Protein A-Sepharose and free
rTACE eluted by enterokinase cleavage, yielding a protein band at
an apparent molecular weight of 43 kDa. N-terminal sequencing of
this protein band showed that it corresponded to the catalytic do-
main of rTACE lacking the pro-domain.
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3.4. Inhibition of rTACE by MMP inhibitors
The design of several MMP inhibitors has been based on
the structural requirements of the active site of MMPs for its
substrates [35]. The nature of the residue occupying the P10
position at the cleavage site is a major determinant in MMP
activity and selectivity. This residue is either leucyl or isoleucyl
in collagen cleaved by collagenase-1 (MMP-1). Consequently,
several inhibitors such as CT-420, Ro-31-9790, BB-94 and
CT-2256 (Fig. 2) have a leucyl-type side chain (isobutyl) in
a position likely to interact with the S10 speci¢city pocket of
collagenases or other MMPs [35]. These inhibitors are usually
broad spectrum MMP inhibitors and their hydroxamate de-
rivatives can also inhibit the shedding of several membrane
proteins [22] as well as TACE [3]. The Ki values reported for
the inhibition of TACE by BB-94, GW9471 and TAPI were
respectively 4.5, 5.7 and 8.1 nM [3]. In our studies, com-
pounds with an isobutyl side chain in the P10 position were
likewise e⁄cient inhibitors of rTACE, particularly BB-94, the
most potent inhibitor tested (Table 1). The value found here
for BB-94 di¡ers slightly from that reported by Moss et al. [3].
Extension of the P10 hydrocarbon chain, as in CT-1746 and
CT-548 (Fig. 2), is well tolerated by MMP-2 but less so by
MMP-1 and rTACE (Table 1, [35]). The lack of inhibition of
rTACE by CT-548 may also be due to the presence of a less
e⁄cient zinc binding group (carboxylate instead of hydroxa-
mate; Table 1). To further study TACE inhibition by hydrox-
amate inhibitors, it would be interesting to try similar com-
pounds bearing an isopropyl group in the P10 position,
thereby mimicking the valyl residue of human proTNF-K at
this position.
3.5. Inhibition of rTACE by TIMPs
The activities of the natural MMP inhibitors, the TIMPs,
against rTACE were assessed using QF-45. TIMP-3 was a
good inhibitor of rTACE, whereas TIMP-2 and TIMP-4
were relatively weak inhibitors and TIMP-1 had no e¡ect
(Table 1). The inhibition of rTACE by TIMP-3 was character-
istic of slow-binding inhibition following a simple bimolecular
association [31]. The estimated second-order association rate
constant kon was 1.013( þ 0.007)U106 M31 s31 and the ¢rst-
order dissociation rate constant koff was 2.01( þ 0.02)U1034
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Fig. 2. Structures of the metalloproteinase inhibitors tested on rTACE.
Table 2
Inhibition of MMP-2 and rTACE by TIMPsa
TIMP MMP-2 rTACE
-1 6 3 N.I.
-2 0.0006b 130 000c
-3 6 2 182
-4 6 4 100 000c
aApparent Ki (pM) except where indicated; bKD (pM); cIC25 (pM);
N.I., no inhibition.
Table 1
Inhibitory activities of metalloproteinase inhibitors towards rTACE
and MMP-1, -2 and -3
Inhibitor rTACE MMP-1 MMP-2 MMP-3
CT-420 85 7.6 2.85 45
CT-548 N.I. 44 700 21 842
CT-1746 126 122 0.04 10.9
Ro-31-9790 21 4.2 1.8 119
BB-94 0.54 1.5 0.26 2
CT-2256 4.8 4.7 10 34.2
Apparent Ki (nM); MMP-1, collagenase-1; MMP-2, gelatinase-A;
MMP-3, stromelysin-1.
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s31 (Fig. 3). Combined, these parameters give a dissociation
constant (Kd) of the EI complex of 198 pM. This value was in
good agreement with the apparent inhibition constant:
Ki 0 = 182( þ 76) pM (Table 2). The high standard error prob-
ably resulted from the e¡ect of prolonged pre-incubation on
enzyme stability [13].
The Ki0 values for the inhibition of MMP-2 by TIMP-1,
-3 and -4 were considerably lower (Table 2). Because
[E]oVKi0 cannot be ful¢lled, the estimates for Ki 0 are less
accurate, with standard errors above 50%. For comparative
purposes only, estimates of Ki0 plus their standard error are
shown in Table 2 as upper limits. TIMP-3 is at least two
orders of magnitude more inhibitory towards MMP-2 than
rTACE. However, the inhibition e¡ect of TIMP-3 on rTACE
is speci¢c, whereas MMP-2 is tightly inhibited by all four
TIMPs. MMP-2 and TIMPs interact not only through their
N-terminal domains, but also through their C-terminal do-
mains which contribute to the overall stability of their com-
plex [24]. This is re£ected by the very low dissociation con-
stant of the MMP-2-TIMP-2 complex determined in our
laboratory: Kd = 6U10316 M [32]. However, for matrilysin
(MMP-7), an MMP that naturally lacks a C-terminal domain,
the inhibition by TIMP-1 (Ki 0 = 370 pM [36]), is comparable
to that of rTACE by TIMP-3. The contribution of the dis-
integrin and cysteine-rich domains to the inhibition of TACE
by TIMP-3 has yet to be determined.
Structural similarities between the active sites of stromely-
sin-1 (MMP-3) and the snake venom metalloproteinase, ada-
malysin II, had previously led Bode and co-workers to pro-
pose that TIMPs may be inhibitors of members of the ADAM
family [16]. This was substantiated by more recent work on
the crystal structure of the TACE catalytic domain [11]. From
our studies we can conclude that only TIMP-3 is likely to be a
physiologically relevant inhibitor of TACE. These data agree
with the observations that cell shedding of the TNF receptor
[19], the IL-6 receptor [20] and TNF-K and L-selectin (manu-
script in preparation) are modulated by TIMP-3 but not by
TIMP-1 or -2. It will be of interest to determine whether other
ADAMs are inhibited by the TIMPs. MADM is a prime
candidate for such studies, because of its relatively high se-
quence identity with TACE compared with other ADAMs [2]
and its proTNF-K converting activity [8,9].
Structural studies of the interactions between TACE and
TIMP-3 by X-ray crystallography or NMR spectroscopy
may provide valuable information for the design of inhibitors
with potential pharmacological applications or TIMP variants
that selectively inhibit TACE, or speci¢c MMPs.
TIMP-3 has the potential to be a physiologically relevant
regulator of ectodomain shedding activities of cells due to its
location within the extracellular matrix. Recent studies have
suggested that TIMP-3 has apoptotic activities against some
cell types which may, in part, be due to the inhibition of the
relevant receptor shedding events [19,37].
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